Clark A, Lewis CE, Willis AC, Cooper GJS, Morris JF, Reid KBM, et al
In Study 3, statistically significantly more patients randomized to SAXENDA than placebo had not gained more than 0.5% of body weight from randomization to Week 56
This time period allows for building the proper foundation for sustained lifestyle and nutrition change to support and maintain weight loss even beyond program enrollment
Structural alterations of the ligand peptides as in GIP/GLP-1 dual-receptor agonists may alter these cellular processes strongly and may explain that an antagonist may activate while an agonist may block receptor signaling (4649)
This is a problem we call the Quality-Price Gap. We put Hers under the microscope to see how it measures up on safety, cost, and long-term support, helping you bridge the gap between safety and affordability